NEW YORK (GenomeWeb News) – Nanosphere announced after the close of the market on Tuesday an agreement to sell up to $30 million of shares of its common stock to investment fund Aspire Capital.

Aspire is an existing investor in Nanosphere and invested in the firm's public offering in September that raised $27.7 million. In a document filed with the US Securities and Exchange Commission on Tuesday, Nanosphere said that the agreement with Aspire has a term of 24 months.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.